Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effects of Zortress + Tacrolimus vs. Standard Immunosuppression on Progression of Coronary Artery Calcifications and Bone Disease in de Novo Renal Transplant Recipients

Next Previous
Search
Trial Profile

Effects of Zortress + Tacrolimus vs. Standard Immunosuppression on Progression of Coronary Artery Calcifications and Bone Disease in de Novo Renal Transplant Recipients

Status: Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 03 Oct 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Everolimus (Primary) ; Corticosteroids; Mycophenolate mofetil; Mycophenolic acid; Tacrolimus
  • Indications Renal transplant rejection
  • Focus Pharmacodynamics

Most Recent Events

  • 04 Aug 2017 Status changed from recruiting to withdrawn prior to enrolment as funding was withdrawn for this study by the sponsor.
  • 07 Aug 2015 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified Aug 2013)
  • 13 Jun 2012 New trial record

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top